A Phase 1 interventional study of dabigatran and Verapamil in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate whether and to what extent the P-glycoprotein inhibitor (P-gp) verapamil affects the pharmacokinetic parameters of dabigatran with verapamil given at different dosages, in different formulations (immediate release (IR) and extended release (ER)), and in different intervals in relation to the dabigatran dose.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The subject is not able to understand and comply with protocol requirements, instructions, protocol-stated restrictions and dietary regimen of study centre
For male subjects:
Male subjects who do not agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post study medical. Acceptable methods of comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two month)
For female subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatments will be given in a fixed sequence
Drug: dabigatran · Drug: Verapamil
Treatments will be given in randomized sequences
Drug: dabigatran · Drug: Verapamil · Drug: Verapamil ER
AUC0-infinity (area under the concentration-time curve of total dabigatran over the time interval from 0 extrapolated to infinity)
Time frame: up to 107 hours
Cmax (maximum measured concentration of total dabigatran)
Time frame: up to 107 hours
AUC0-infinity (area under the concentration-time curve of free dabigatran over the time interval from 0 extrapolated to infinity)
Time frame: up to 107 hours
Cmax (maximum measured concentration of free dabigatran)
Time frame: up to 107 hours
AUC0-infinity (area under the concentration-time curve of verapamil over the time interval from 0 extrapolated to infinity)
Time frame: up to 107 hours
Cmax (maximum measured concentration of verapamil)
Time frame: up to 107 hours
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
Time frame: up to 107 hours
AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h after the administration)
Time frame: up to 107 hours
tmax (time from dosing to the maximum concentration of the analyte in plasma)
Time frame: up to 107 hours
λz (terminal rate constant in plasma)
Time frame: up to 107 hours
t1/2 (terminal half-life of the analyte in plasma)
Time frame: up to 107 hours
MRTpo (mean residence time of the analyte in the body after oral administration)
Time frame: up to 107 hours
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
Time frame: up to 107 hours
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Time frame: up to 107 hours
AUCτ,ss (area under the concentration-time curve of verapamil within the uniform dosing interval τ)
Time frame: up to 107 hours
AUC0-tz,ss (area under the concentration-time curve of verapamil from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)
Time frame: up to 107 hours
Cmax,ss (maximum concentration of verapamil at steady state)
Time frame: up to 107 hours
tz,ss (time of last measureable concentration of verapamil within the dosing interval τ at steady state)
Time frame: up to 107 hours
tmax,ss (time from last dosing to the maximum concentration of verapamil at steady state on day 4)
Time frame: up to 107 hours
CL/F,ss (apparent clearance of verapamil at steady state after extravascular multiple dose administration)
Time frame: up to 107 hours
Cmin,ss (minimum measured concentration of verapamil at steady state over a uniform dosing interval τ)
Time frame: up to 107 hours
tmin,ss (time from last dosing to the minimum concentration of verapamil at steady state over a uniform dosing interval τ)
Time frame: up to 107 hours
Cpre,ss (predose concentration of verapamil at steady state immediately before administration of the next dose)
Time frame: up to 107 hours
Cavg (Average concentration of verapamil at steady state)
Time frame: up to 107 hours
MRTpo,ss (mean residence time of verapamil in the body at steady state after oral administration)
Time frame: up to 107 hours
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)
Time frame: up to 107 hours
Ae0-24 (amount of dabigatran that is eliminated in urine from the time interval 0-24h)
Time frame: up to 107 hours
fe0-24 (fraction of administered drug excreted unchanged in urine from time point 0- 24h)
Time frame: up to 107 hours
CLR0-24 (renal clearance of dabigatran from the time point 0 until the time point 24h )
Time frame: up to 107 hours
AUEC0-24 (area under the effect curve)
for ecarin clotting time and thrombin time
Time frame: up to 107 hours
ERmax (maximum effect ratio)
for ecarin clotting time and thrombin time
Time frame: up to 107 hours
Occurence of Adverse Events
Time frame: within 5 days after last drug administration
Assessment of Tolerability by investigator
Time frame: within 5 days after last drug administration
No study locations are listed for this record.
The record gives a start of Jun 2008 and a primary completion of Aug 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dabigatran · Verapamil